WallStreetZenWallStreetZen

NYSE: GSK
Gsk PLC Earnings Dates, Reports, Calls

OverviewEarnings
RevenueDividendOwnership
Gsk earnings were $7.7B for the trailing 12 months ending Dec 31, 2025, with 141.4% growth year over year. The latest GSK earnings report on Dec 31, 2025 announced Q4 2025 earnings of $859.5M, down 68.4% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, GSK reported annual earnings of $7.7B, with 140% growth. The next GSK earnings date is Apr 29, 2026.

GSK past earnings growth

How has GSK's earnings growth performed historically?

Company
141.39%
Industry
136.3%
Market
87.5%
GSK's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
GSK's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
GSK's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

GSK earnings history

Current Revenue
$44.1B
Current Earnings
$7.7B
Current Profit Margin
17.5%
GSK's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

GSK Return on Equity

Current Company
37.2%
Current Industry
8.1%
Current Market
28.9%
GSK's Return on Equity (37.2%)... subscribe to Premium to read more.
High Return on Equity Performance

GSK Return on Assets

Current Company
9.4%
Current Industry
12.6%
GSK is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when GSK announces earnings.

GSK Return on Capital Employed

Current Company
18.95%
Current Industry
21.4%
GSK's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

GSK vs General Drug Manufacturer Stocks

TickerEBITDAEarningsY/Y EarningsEPS
GSK$10.17B$7.72B-0.73%$3.81
SNY$17.97B$9.30B-8.84%$3.81
BMY$13.34B$7.05B+2.45%$3.47
PFE$14.10B$7.77B-3.65%$1.37
GILD$13.58B$8.51B+132.82%$6.84
View Top General Drug Manufacturer Stocks

GSK earnings dates

Next earnings date
Apr 29, 2026

Gsk Earnings Reports & History FAQ

What were Gsk's earnings last quarter?

On GSK's earnings call on Invalid Date, Gsk (NYSE: GSK) reported Q4 2025 earnings per share (EPS) of $0.43, up 69.41% year over year. Total GSK earnings for the quarter were $859.46 million. In the same quarter last year, Gsk's earnings per share (EPS) was $0.26.

If you're new to stock investing, here's how to buy Gsk stock.

When does Gsk report earnings?

The next GSK earnings date is Invalid Date. Add GSK to your watchlist to be reminded of Gsk's next earnings date.

Is Gsk profitable or losing money?

As of the last Gsk earnings report, Gsk is currently profitable. Gsk's net profit (also called net income) for the twelve months ending Dec 31, 2025 was $7.72 billion, a 139.98% increase year over year.

What was GSK's earnings growth in the past year?

As of Gsk's earnings date in Invalid Date, Gsk's earnings has grown 141.39% year over year. This is 5.09 percentage points higher than the US Drug Manufacturers - General industry earnings growth rate of 136.3%. GSK earnings in the past year totalled $7.72 billion.

What are Gsk's earnings expectations?

The current EPS estimate for Gsk's earnings report in Invalid Date is $1.20.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.